RO120243B1 - Procedee de preparare a unor formule de hidrolizat proteic, pentru prevenirea sau tratarea alergiilor şi utilizarea acestora - Google Patents
Procedee de preparare a unor formule de hidrolizat proteic, pentru prevenirea sau tratarea alergiilor şi utilizarea acestora Download PDFInfo
- Publication number
- RO120243B1 RO120243B1 RO97-02328A RO9702328A RO120243B1 RO 120243 B1 RO120243 B1 RO 120243B1 RO 9702328 A RO9702328 A RO 9702328A RO 120243 B1 RO120243 B1 RO 120243B1
- Authority
- RO
- Romania
- Prior art keywords
- formula
- preparation
- lactobacillus
- casein
- protein hydrolyzate
- Prior art date
Links
- 239000003531 protein hydrolysate Substances 0.000 title claims abstract description 28
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000008569 process Effects 0.000 title claims abstract description 9
- 108010009736 Protein Hydrolysates Proteins 0.000 title abstract description 5
- 230000007815 allergy Effects 0.000 title abstract description 4
- 241000186660 Lactobacillus Species 0.000 claims abstract description 39
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 19
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- 201000010859 Milk allergy Diseases 0.000 claims abstract description 9
- 230000004888 barrier function Effects 0.000 claims abstract description 8
- 208000009793 Milk Hypersensitivity Diseases 0.000 claims abstract description 7
- 230000028993 immune response Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 229940088598 enzyme Drugs 0.000 claims description 17
- 102000057297 Pepsin A Human genes 0.000 claims description 14
- 108090000284 Pepsin A Proteins 0.000 claims description 14
- 229940111202 pepsin Drugs 0.000 claims description 14
- 102000004142 Trypsin Human genes 0.000 claims description 13
- 108090000631 Trypsin Proteins 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 210000000936 intestine Anatomy 0.000 claims description 12
- 239000012588 trypsin Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 9
- 230000007062 hydrolysis Effects 0.000 claims description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000007065 protein hydrolysis Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000020247 cow milk Nutrition 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 230000000529 probiotic effect Effects 0.000 abstract description 4
- 230000009885 systemic effect Effects 0.000 abstract description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract description 2
- 206010016946 Food allergy Diseases 0.000 abstract description 2
- 239000013566 allergen Substances 0.000 abstract description 2
- 201000005356 cow milk allergy Diseases 0.000 abstract description 2
- 235000020932 food allergy Nutrition 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 235000020883 elimination diet Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004046 hyporesponsiveness Effects 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
- 239000005018 casein Substances 0.000 description 38
- 102000011632 Caseins Human genes 0.000 description 36
- 108010076119 Caseins Proteins 0.000 description 36
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 36
- 235000021240 caseins Nutrition 0.000 description 36
- 206010012438 Dermatitis atopic Diseases 0.000 description 13
- 201000008937 atopic dermatitis Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 101710081722 Antitrypsin Proteins 0.000 description 9
- 230000001475 anti-trypsic effect Effects 0.000 description 9
- 239000002753 trypsin inhibitor Substances 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- 206010003645 Atopy Diseases 0.000 description 7
- 239000005862 Whey Substances 0.000 description 7
- 102000007544 Whey Proteins Human genes 0.000 description 7
- 108010046377 Whey Proteins Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000017307 interleukin-4 production Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000010093 eczematous lesion Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI952926A FI104465B (fi) | 1995-06-14 | 1995-06-14 | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| PCT/FI1996/000350 WO1997000078A1 (en) | 1995-06-14 | 1996-06-12 | Methods of preventing or treating allergies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RO120243B1 true RO120243B1 (ro) | 2005-11-30 |
Family
ID=8543602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RO97-02328A RO120243B1 (ro) | 1995-06-14 | 1996-06-12 | Procedee de preparare a unor formule de hidrolizat proteic, pentru prevenirea sau tratarea alergiilor şi utilizarea acestora |
Country Status (26)
Families Citing this family (168)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| AU750136B2 (en) * | 1997-06-03 | 2002-07-11 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS |
| EP1108781A3 (en) | 1999-01-19 | 2001-09-12 | Maxygen, Inc. | Method for making character strings, polynucleotides and polypeptides |
| US6926891B1 (en) | 1999-08-05 | 2005-08-09 | Nestec S.A. | Treatment of diarrhea with strains of Bifidobacterium longum |
| DK1353681T3 (da) | 1999-08-05 | 2008-03-10 | Nestle Sa | Bifidobakterier i stand til at modvirke diarré |
| US20020031787A1 (en) * | 2000-02-04 | 2002-03-14 | Maclaren Noel K. | Compositions and methods for reducing autoimmunity |
| FI110668B (fi) | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
| AU2056102A (en) | 2000-09-25 | 2002-04-02 | Nestle Sa | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
| JP4510376B2 (ja) * | 2000-10-06 | 2010-07-21 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 皮膚の免疫系のバランスを保つためのプロバイオティック乳酸菌の使用 |
| FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
| EP1228707A1 (en) * | 2001-02-01 | 2002-08-07 | Campina Melkunie B.V. | Use of alpha-lactalbumin as prebiotic agent |
| WO2002071874A2 (en) * | 2001-03-09 | 2002-09-19 | Societe Des Produits Nestle S.A. | Composition improving age-related physiological deficits and increasing longevity |
| JP2003137804A (ja) * | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−１８誘導剤 |
| EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
| WO2003102195A1 (en) | 2002-06-04 | 2003-12-11 | Dsm Ip Assets B.V. | Protein hydrolysate rich in tripeptides |
| US20040057943A1 (en) | 2002-06-28 | 2004-03-25 | Jordi Xaus Pey | Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
| US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| CA2530437C (en) * | 2003-06-23 | 2011-11-15 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
| CN101671680B (zh) | 2004-02-25 | 2012-11-28 | 先锋高级育种国际公司 | 新的苏云金芽孢杆菌晶体多肽、多核苷酸及其组合物 |
| US20050265946A1 (en) * | 2004-05-28 | 2005-12-01 | Kao Corporation | Elastase inhibitor |
| US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| CN101193559A (zh) | 2005-04-13 | 2008-06-04 | 雀巢技术公司 | 具有益生菌的婴儿配方食品 |
| US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| CN101325880B (zh) * | 2005-11-14 | 2012-03-28 | 雀巢技术公司 | 用糖化蛋白质促进口服耐受性 |
| CN101420965B (zh) | 2006-02-15 | 2013-08-07 | 雀巢产品技术援助有限公司 | 长双歧杆菌在制备预防和治疗炎症的药物中的用途 |
| PL1993576T3 (pl) | 2006-03-07 | 2016-04-29 | Nestec Sa | Mieszanina synbiotyczna |
| PL2031986T3 (pl) * | 2006-06-15 | 2013-08-30 | Nestec Sa | Wywoływanie tolerancji na białka jaja |
| ATE544457T1 (de) * | 2007-02-28 | 2012-02-15 | Mead Johnson Nutrition Co | Verfahren zur behandlung bzw. prävention systemischer entzündungen |
| EP1974734A1 (en) † | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| EP1974735A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Reduction of risk of diarrhoea |
| CN101273737B (zh) * | 2007-03-28 | 2011-08-24 | 哈尔滨正方科技有限公司 | 一种在常温下保持高活菌数的发酵乳饮料的制备方法 |
| CN101784669B (zh) | 2007-08-24 | 2015-02-18 | 科德克希思公司 | 用于(r)-3-羟基四氢噻吩的立体选择性制备的改善的酮还原酶多肽 |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| WO2009092628A1 (en) | 2008-01-24 | 2009-07-30 | Nestec S.A. | Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule |
| DK2244734T3 (en) | 2008-02-01 | 2016-08-15 | Murdoch Childrens Res Inst | PROCEDURE FOR INDUCTION OF TOLERANCE ABOUT AN ALLERGY |
| WO2009112361A2 (en) | 2008-03-14 | 2009-09-17 | Nestec S.A. | Synbiotic mixture |
| EP2127661A1 (en) | 2008-05-27 | 2009-12-02 | Nestec S.A. | Probiotics to improve gut microbiotica |
| DK2285958T3 (en) | 2008-06-13 | 2016-03-29 | Codexis Inc | Method for synthesizing polynucleotides |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| EP2307419B1 (en) | 2008-06-24 | 2013-11-06 | Codexis, Inc. | Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds |
| EP2147678A1 (en) | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
| RU2392001C2 (ru) * | 2008-08-04 | 2010-06-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ лечения желтушных форм вирусного гепатита а у детей с пищевой аллергией |
| US8426178B2 (en) | 2008-08-27 | 2013-04-23 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| US8470564B2 (en) | 2009-01-08 | 2013-06-25 | Codexis, Inc. | Transaminase polypeptides |
| EP2408908B1 (en) | 2009-03-17 | 2015-05-27 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
| BRPI1010239A2 (pt) | 2009-03-31 | 2016-10-11 | Codexis Inc | endoglucanases aprimoradas, derivados e seus usos |
| CA2762616C (en) | 2009-06-16 | 2015-08-18 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| CN102482648B (zh) | 2009-06-22 | 2014-12-10 | 科德克希思公司 | 酮还原酶介导的产生α氯代醇的立体选择性途径 |
| WO2011011630A2 (en) | 2009-07-23 | 2011-01-27 | Codexis, Inc. | Nitrilase biocatalysts |
| SG178139A1 (en) * | 2009-08-18 | 2012-03-29 | Nestec Sa | A nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children. |
| WO2011020748A1 (en) | 2009-08-18 | 2011-02-24 | Nestec S.A. | A nutritional composition comprising bifidobacterium longum strains and reducing food allergy symptoms, especially in infants and children |
| SG10201405022PA (en) | 2009-08-19 | 2014-10-30 | Codexis Inc | Ketoreductase polypeptides for the preparation of phenylephrine |
| EP2473604B1 (en) | 2009-09-04 | 2017-01-11 | Codexis, Inc. | Variant cbh2 cellulases and related polynucleotides |
| EP2295535A1 (en) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotic material |
| DK2478137T3 (da) | 2009-09-18 | 2017-11-27 | Codexis Inc | Reduceret kodonmutagenese |
| US8652813B2 (en) | 2009-11-25 | 2014-02-18 | Codexis, Inc. | Recombinant Thermoascus aurantiacus β-glucosidase variants |
| RU2012126131A (ru) | 2009-11-25 | 2013-12-27 | Кодексис, Инк. | РЕКОМБИНАНТНЫЕ ВАРИАНТЫ β-ГЛЮКОЗИДАЗЫ ДЛЯ ПРОДУКЦИИ РАСТВОРИМЫХ САХАРОВ ИЗ ЦЕЛЛЮЛОЗНОЙ БИОМАССЫ |
| US9226521B2 (en) | 2009-12-08 | 2016-01-05 | Nestec S.A. | Infant formula with probiotics and milk fat globule membrane components |
| US8895271B2 (en) | 2009-12-08 | 2014-11-25 | Codexis, Inc. | Synthesis of prazole compounds |
| CA2786001A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
| EP2566497B1 (en) | 2010-05-04 | 2015-07-29 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
| EP2569331A1 (en) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptide inhibitors of vla4 |
| US20110294170A1 (en) | 2010-05-28 | 2011-12-01 | Codexis, Inc. | Pentose Fermentation By a Recombinant Microorganism |
| DK2582799T3 (en) | 2010-06-17 | 2018-02-12 | Codexis Inc | BIOCATALATORS AND PROCEDURES FOR THE SYNTHESIS OF (S) -3- (1-AMINOETHYL) -PHENOL |
| CA2804019A1 (en) | 2010-06-28 | 2012-01-12 | Codexis, Inc. | Fatty alcohol forming acyl reductases (fars) and methods of use thereof |
| US8420364B2 (en) | 2010-06-30 | 2013-04-16 | Codexis, Inc. | Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
| EP2605772B1 (en) | 2010-08-16 | 2016-06-22 | Cardiome International AG | Process for preparing aminocyclohexyl ether compounds |
| CA2807702C (en) | 2010-08-20 | 2018-07-24 | Codexis, Inc. | Use of glycoside hydrolase 61 family proteins in processing of cellulose |
| WO2012078800A2 (en) | 2010-12-08 | 2012-06-14 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
| EE05721B1 (et) | 2011-02-25 | 2014-08-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tüvi L. plantarum MCC1 DSM 23881 ja selle kasutamine |
| WO2012135110A1 (en) | 2011-03-30 | 2012-10-04 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| HUE038800T2 (hu) | 2011-04-13 | 2018-11-28 | Codexis Inc | Biokatalitikus eljárás eszlikarbazepin és ennek analógjai elõállítására |
| UA111078C2 (uk) * | 2011-05-03 | 2016-03-25 | Нестек С.А. | Гідролізат білкового субстрату і спосіб його виготовлення |
| US8778652B2 (en) | 2011-06-30 | 2014-07-15 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| BR112014004171A2 (pt) | 2011-08-22 | 2018-11-06 | Codexis Inc | variantes da proteína glicósideo hidrolase gh61 e cofatores que aumentam a atividade de gh61 |
| WO2013036861A1 (en) | 2011-09-08 | 2013-03-14 | Codexis, Inc | Biocatalysts and methods for the synthesis of substituted lactams |
| US20130084608A1 (en) | 2011-09-30 | 2013-04-04 | Codexis, Inc. | Fungal proteases |
| US20130084271A1 (en) * | 2011-10-03 | 2013-04-04 | Kelly Foods Corporation | Probiotic composition for pets and method of providing the same |
| US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
| SG11201402401TA (en) | 2011-11-18 | 2014-06-27 | Codexis Inc | Biocatalysts for the preparation of hydroxy substituted carbamates |
| US9611462B2 (en) | 2011-12-20 | 2017-04-04 | Codexis, Inc. | Endoglucanase 1B (EG1B) variants |
| SG11201405990PA (en) | 2012-03-23 | 2014-11-27 | Codexis Inc | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
| US20130251829A1 (en) * | 2012-03-23 | 2013-09-26 | Mead Johnson Nutrition Company | Probiotic derived non-viable material for infection prevention and treatment |
| ES2712682T3 (es) | 2012-05-08 | 2019-05-14 | Codexis Inc | Biocatalizadores y métodos para la hidroxilación de compuestos químicos |
| CN107904216B (zh) | 2012-05-11 | 2021-06-29 | 科德克希思公司 | 工程化亚胺还原酶以及用于酮和胺化合物的还原胺化的方法 |
| WO2013188305A2 (en) | 2012-06-11 | 2013-12-19 | Codexis, Inc. | Fungal beta-xylosidase variants |
| US9611515B2 (en) | 2012-11-20 | 2017-04-04 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| EP3406594A1 (en) | 2012-12-07 | 2018-11-28 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| CN120829884A (zh) | 2012-12-21 | 2025-10-24 | 科德克希思公司 | 用于合成手性胺的工程化的生物催化剂和方法 |
| CA2898495C (en) | 2013-01-18 | 2021-06-01 | Codexis, Inc. | Engineered biocatalysts useful for carbapenem synthesis |
| DK2961844T3 (da) | 2013-02-28 | 2019-01-02 | Codexis Inc | Modificerede transaminasepolypeptider til industriel biokatalyse |
| CN103355405A (zh) * | 2013-04-07 | 2013-10-23 | 苏州旭优食品科技有限公司 | 一种低过敏性含乳制品的加工工艺 |
| KR102218930B1 (ko) | 2013-04-18 | 2021-02-23 | 코덱시스, 인코포레이티드 | 조작된 페닐알라닌 암모니아 리아제 폴리펩티드 |
| JP6643987B2 (ja) | 2013-11-13 | 2020-02-12 | コデクシス， インコーポレイテッド | ケトン化合物およびアミン化合物の還元的アミノ化のための操作されたイミンレダクターゼおよび方法 |
| CA2943432A1 (en) | 2014-04-16 | 2015-10-22 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| US9708587B2 (en) | 2014-07-09 | 2017-07-18 | Codexis, Inc. | P450-BM3 variants with improved activity |
| JP6719463B2 (ja) | 2014-11-25 | 2020-07-15 | コデクシス， インコーポレイテッド | ケトン化合物およびアミン化合物の還元的アミノ化のための操作されたイミンレダクターゼおよび方法 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| KR102702200B1 (ko) | 2014-12-22 | 2024-09-02 | 코덱시스, 인코포레이티드 | 인간 알파-갈락토시다제 변이체 |
| ES2830725T3 (es) | 2015-02-10 | 2021-06-04 | Codexis Inc | Polipéptidos cetoreductasa para la síntesis de compuestos quirales |
| JP6755886B2 (ja) | 2015-05-07 | 2020-09-16 | コデクシス， インコーポレイテッド | ペニシリンｇアシラーゼ |
| WO2017007547A1 (en) | 2015-07-07 | 2017-01-12 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
| KR102382489B1 (ko) | 2016-05-05 | 2022-04-01 | 코덱시스, 인코포레이티드 | 페니실린 ｇ 아실라제 |
| US10184117B2 (en) | 2016-06-09 | 2019-01-22 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| KR20190018512A (ko) | 2016-06-15 | 2019-02-22 | 코덱시스, 인코포레이티드 | 조작된 베타-글루코시다아제 및 글루코실화 방법 |
| EP3515926B1 (en) | 2016-08-26 | 2023-10-25 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| WO2018129130A1 (en) | 2017-01-05 | 2018-07-12 | Codexis, Inc. | Penicillin-g acylases |
| CN110914445B (zh) | 2017-02-03 | 2024-08-27 | 泰莱解决方案美国有限责任公司 | 工程化糖基转移酶和甜菊醇糖苷葡糖基化方法 |
| WO2018148633A1 (en) | 2017-02-13 | 2018-08-16 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| SG11201909712TA (en) | 2017-04-27 | 2019-11-28 | Codexis Inc | Ketoreductase polypeptides and polynucleotides |
| CA3062550A1 (en) | 2017-05-08 | 2018-11-15 | Codexis, Inc. | Engineered ligase variants |
| CN111032682B (zh) | 2017-06-14 | 2024-04-12 | 科德克希思公司 | 用于工业生物催化的工程化转氨酶多肽 |
| US11643642B2 (en) | 2017-06-27 | 2023-05-09 | Codexis, Inc. | Penicillin-g acylases |
| JP7588391B2 (ja) | 2017-06-30 | 2024-11-22 | コデクシス， インコーポレイテッド | Ｔ７ ｒｎａポリメラーゼバリアント |
| CN111417724A (zh) | 2017-06-30 | 2020-07-14 | 科德克希思公司 | T7 rna聚合酶变体 |
| EP3706780A4 (en) | 2017-11-07 | 2021-12-22 | Codexis, Inc. | TRANSGLUTAMINASE VARIANTS |
| WO2019118557A1 (en) | 2017-12-13 | 2019-06-20 | Codexis, Inc. | Carboxyesterase polypeptides for amide coupling |
| CA3085261A1 (en) | 2017-12-13 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Carboxyesterase biocatalysts |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3821015A4 (en) | 2018-07-09 | 2022-07-13 | Codexis, Inc. | GENETIC DEOXYRIBOSE PHOSPHATE ALDOLASES |
| MX2021000323A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variante de pantotenato quinasa modificadas geneticamente. |
| MX2021000322A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variante fosfopentomutasa modificada geneticamente. |
| SG11202012111UA (en) | 2018-07-09 | 2021-01-28 | Codexis Inc | Engineered purine nucleoside phosphorylase variant enzymes |
| JP7491587B2 (ja) | 2018-07-09 | 2024-05-28 | コデクシス， インコーポレイテッド | 操作されたガラクトースオキシダーゼ改変体酵素 |
| SG11202012198QA (en) | 2018-07-12 | 2021-01-28 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| JP7584401B2 (ja) | 2018-07-30 | 2024-11-15 | テイト アンド ライル ソリューションズ ユー・エス・エー エル・エル・シー | 操作されたグリコシルトランスフェラーゼおよびステビオールグリコシドのグルコシル化方法 |
| US11060075B2 (en) | 2018-10-29 | 2021-07-13 | Codexis, Inc. | Engineered DNA polymerase variants |
| WO2020123286A1 (en) | 2018-12-14 | 2020-06-18 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| CN113544268A (zh) | 2018-12-20 | 2021-10-22 | 科德克希思公司 | 人类α半乳糖苷酶变体 |
| SG11202106617VA (en) | 2019-01-15 | 2021-07-29 | Codexis Inc | Engineered transaminase polypeptides |
| WO2020223102A1 (en) | 2019-05-01 | 2020-11-05 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| US12215359B2 (en) | 2019-05-01 | 2025-02-04 | Codexis, Inc. | Engineered glucose dehydrogenases and methods for the reductive amination of ketone and amine compounds |
| WO2021003132A1 (en) | 2019-07-02 | 2021-01-07 | Codexis, Inc. | Engineered sucrose phosphorylase variant enzymes |
| US12275962B2 (en) | 2019-07-02 | 2025-04-15 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| EP4581941A3 (en) | 2019-07-23 | 2025-09-10 | FrieslandCampina Nederland B.V. | Nutritional composition comprising milk fat and immunoglobulin |
| KR20220106738A (ko) | 2019-08-30 | 2022-07-29 | 코덱시스, 인코포레이티드 | 조작된 리파제 변이체 |
| CA3149870A1 (en) | 2019-09-12 | 2021-03-18 | Codexis, Inc. | Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine |
| CN114746745B (zh) | 2019-10-02 | 2025-06-17 | 美国雅培糖尿病护理公司 | 通过蛋白质开关检测分析物 |
| US12344865B2 (en) | 2019-11-26 | 2025-07-01 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| JP2023507575A (ja) | 2019-12-20 | 2023-02-24 | コデクシス， インコーポレイテッド | 操作された酸性アルファ－グルコシダーゼバリアント |
| KR20220137057A (ko) | 2020-02-04 | 2022-10-11 | 코덱시스, 인코포레이티드 | 조작된 류신 데카르복실라제 |
| US11788071B2 (en) | 2020-04-10 | 2023-10-17 | Codexis, Inc. | Engineered transaminase polypeptides |
| CA3191867A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered protease variants |
| BR112023003643A2 (pt) | 2020-08-28 | 2023-03-28 | Codexis Inc | Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso |
| US20220186231A1 (en) | 2020-12-11 | 2022-06-16 | Willow Biosciences, Inc. | Recombinant acyl activating enzyme (aae) genes for enhanced biosynthesis of cannabinoids and cannabinoid precursors |
| EP4262804A4 (en) | 2020-12-18 | 2025-02-12 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| CA3214972A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered adenylate kinase variant enzymes |
| CN117120599A (zh) | 2021-04-02 | 2023-11-24 | 科德克希思公司 | 工程化鸟苷酸激酶变体酶 |
| WO2022212835A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| WO2022212832A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered cyclic gmp-amp synthase (cgas) variant enzymes |
| EP4341395A4 (en) | 2021-05-21 | 2025-07-23 | Syntis Bio Inc | MODIFIED METHIONINE GAMMA LYASE VARIANTS |
| CA3227215A1 (en) | 2021-07-30 | 2023-02-02 | Trish Choudhary | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| EP4388088A1 (en) | 2021-08-19 | 2024-06-26 | Willow Biosciences, Inc. | Recombinant olivetolic acid cyclase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| JP2024539636A (ja) | 2021-10-15 | 2024-10-29 | コデクシス， インコーポレイテッド | 操作されたｄｎａポリメラーゼバリアント |
| WO2023069921A1 (en) | 2021-10-19 | 2023-04-27 | Epimeron Usa, Inc. | Recombinant thca synthase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| AU2022377148A1 (en) | 2021-11-01 | 2024-06-13 | Syntis Bio, Inc. | Engineered leucine decarboxylases |
| WO2023185184A1 (zh) | 2022-03-31 | 2023-10-05 | 青岛清原化合物有限公司 | 一种单胺氧化酶及其应用 |
| EP4573553A1 (en) | 2022-08-15 | 2025-06-25 | ABSCI Corporation | Quantitative affinity activity specific cell enrichment |
| IL322082A (en) | 2023-01-12 | 2025-09-01 | Novartis Ag | Engineered ketoreductase polypeptides |
| WO2025061911A1 (en) | 2023-09-22 | 2025-03-27 | Glaxosmithkline Intellectual Property Development Limited | Methods of producing nucleotide triphosphates (ntps) |
| WO2025144700A1 (en) | 2023-12-27 | 2025-07-03 | Absci Corporation | Nanobody library screening using bacterial surface display |
| WO2025235589A1 (en) | 2024-05-08 | 2025-11-13 | Codexis, Inc. | Dna polymerase variants |
| WO2025242702A1 (en) | 2024-05-23 | 2025-11-27 | Glaxosmithkline Intellectual Property Development Limited | Enzymatic process for producing n-acetyl galactosamine clusters |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886288A (en) * | 1970-06-15 | 1975-05-27 | Swift & Co | Cheese manufacture using highly active proteolytic enzymes |
| JPS5279086A (en) | 1975-12-25 | 1977-07-02 | Nippon Soda Co Ltd | Preparation of antibiotic tunicamycin |
| JPS5279083A (en) * | 1975-12-26 | 1977-07-02 | Morinaga Milk Industry Co Ltd | Production of protein decomposed substance not having bitterness and antigen property |
| JPS6041751B2 (ja) | 1976-06-22 | 1985-09-18 | ジエコ−株式会社 | デジタル電子時計 |
| JPS548785A (en) | 1977-06-21 | 1979-01-23 | Kikkoman Corp | Preparation of protein hydrolyzate |
| US4839281A (en) † | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
| ATE84680T1 (de) † | 1987-12-23 | 1993-02-15 | Nestle Sa | Verfahren zur herstellung eines molkeeiweisshydrolysates und eines hypoallergenen nahrungsmittels. |
| DD281540A5 (de) * | 1988-08-08 | 1990-08-15 | Berlin Chemie Veb | Verfahren zur herstellung von nutritiva |
| EP0421309B2 (en) † | 1989-10-02 | 2001-08-16 | Novartis Nutrition AG | Protein hydrolysates |
| JP3071877B2 (ja) † | 1991-06-27 | 2000-07-31 | 財団法人糧食研究会 | 経口寛容誘導能を有する低アレルゲン性酵素分解ペプチド組成物 |
| US5952034A (en) * | 1991-10-12 | 1999-09-14 | The Regents Of The University Of California | Increasing the digestibility of food proteins by thioredoxin reduction |
| DE69223615T2 (de) * | 1992-07-06 | 1998-04-09 | Nestle Sa | Lactobacillus Acidophilus enthaltende Antigastritis-Mittel |
| FI94089C (fi) | 1992-12-10 | 1995-07-25 | Valio Oy | Menetelmä allergiaa aiheuttavien yhdisteiden poistamiseksi proteiinipitoisista koostumuksista |
| RU2031586C1 (ru) | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
| GB9312369D0 (en) * | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
| WO1995014485A1 (en) † | 1993-11-23 | 1995-06-01 | Kabushiki Kaisha Wado Doctors Group | Intestinal flora improver composition, and apparatus and system for producing the same |
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
-
1995
- 1995-06-14 FI FI952926A patent/FI104465B/fi not_active IP Right Cessation
-
1996
- 1996-06-11 MY MYPI96002357A patent/MY113912A/en unknown
- 1996-06-12 NZ NZ310478A patent/NZ310478A/xx not_active IP Right Cessation
- 1996-06-12 RO RO97-02328A patent/RO120243B1/ro unknown
- 1996-06-12 EP EP96918707A patent/EP0833649B2/en not_active Expired - Lifetime
- 1996-06-12 WO PCT/FI1996/000350 patent/WO1997000078A1/en not_active Ceased
- 1996-06-12 CA CA2224320A patent/CA2224320C/en not_active Expired - Lifetime
- 1996-06-12 BR BR9607827-8A patent/BR9607827A/pt not_active Application Discontinuation
- 1996-06-12 KR KR1019970709383A patent/KR100494741B1/ko not_active Expired - Lifetime
- 1996-06-12 US US08/973,963 patent/US6506380B1/en not_active Expired - Lifetime
- 1996-06-12 AT AT96918707T patent/ATE230606T1/de active
- 1996-06-12 ES ES96918707T patent/ES2191103T5/es not_active Expired - Lifetime
- 1996-06-12 DK DK96918707T patent/DK0833649T4/da active
- 1996-06-12 SK SK1715-97A patent/SK284245B6/sk not_active IP Right Cessation
- 1996-06-12 DE DE69625690T patent/DE69625690T3/de not_active Expired - Lifetime
- 1996-06-12 CZ CZ19973997A patent/CZ291904B6/cs not_active IP Right Cessation
- 1996-06-12 JP JP50267197A patent/JP3983804B2/ja not_active Expired - Lifetime
- 1996-06-12 IL IL12257796A patent/IL122577A0/xx not_active IP Right Cessation
- 1996-06-12 PL PL96324010A patent/PL185123B1/pl unknown
- 1996-06-12 CN CNB961947527A patent/CN1154506C/zh not_active Expired - Lifetime
- 1996-06-12 EE EE9700339A patent/EE03424B1/xx unknown
- 1996-06-13 AR ARP960103134A patent/AR003960A1/es unknown
- 1996-06-14 ZA ZA965088A patent/ZA965088B/xx unknown
-
1997
- 1997-12-11 MX MX9710109A patent/MX9710109A/es unknown
- 1997-12-11 NO NO19975832A patent/NO321504B1/no not_active IP Right Cessation
- 1997-12-23 BG BG102144A patent/BG63153B1/bg unknown
-
2002
- 2002-12-18 US US10/321,661 patent/US7172756B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RO120243B1 (ro) | Procedee de preparare a unor formule de hidrolizat proteic, pentru prevenirea sau tratarea alergiilor şi utilizarea acestora | |
| Kirjavainen et al. | New aspects of probiotics–a novel approach in the management of food allergy. | |
| JP5785275B2 (ja) | 単離された微生物菌株、ラクトバチルスプランタルム（ｌａｃｔｏｂａｃｉｌｌｕｓｐｌａｎｔａｒｕｍ）ｍｃｃ１ｄｓｍ２３８８１およびラクトバチルスガセリ（ｌａｃｔｏｂａｃｉｌｌｕｓｇａｓｓｅｒｉ）ｍｃｃ２ｄｓｍ２３８８２ならびにそれらの使用 | |
| JP2011021015A (ja) | ヘリコバクター属（Ｈｅｌｉｃｏｂａｃｔｅｒ）により引き起こされる炎症を低下させるための乳酸菌の選択および使用 | |
| Caramia et al. | Probiotics and the skin | |
| Pescuma et al. | Hydrolysate of β-lactoglobulin by Lactobacillus delbrueckii subsp. bulgaricus CRL 656 suppresses the immunoreactivity of β-lactoglobulin as revealed by in vivo assays | |
| JP4064480B2 (ja) | ＩｇＧ抗体産生抑制剤 | |
| Cukrowska et al. | Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis | |
| Crane | Pro and anti: the biotics of allergic disease | |
| Ahmad et al. | Probiotic potential of lactic acid to improve immunity during COVID‐19 pandemic (a mini review) | |
| RU2174012C2 (ru) | Способы профилактики или лечения аллергии | |
| Adi et al. | The effect of probiotic biscuit on Faecal microbiota in malnourished children | |
| AU710126C (en) | Methods of preventing or treating allergies | |
| Shin et al. | Enhancement of immunological activity in mice with oral administration of cell wall components of Bifidobacterium bifidum | |
| HK1010081B (en) | Methods of preventing or treating allergies | |
| GURR | Health benefits of cultured and culture‐containing milks | |
| Meena et al. | Effect of Lactobacillus helveticus and Dahi on β-Glucuronidase and β-Galactosidase Enzyme Activities in Mice against Infection of Salmonella enteritidis |